D-1333-2020 Class II Terminated
FDA drug recall D-1333-2020 was initiated by PD-Rx Pharmaceuticals, Inc. on Jun 5, 2020 and is designated Class II. Reason for recall: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level The recall status is terminated (terminated Nov 8, 2021). Affected quantity: 1969 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 1, 2020
- Initiation Date
- Jun 5, 2020
- Termination Date
- Nov 8, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1969 bottles
Product description
metFORMIN HCL ER 500 mg, a) 30 tablets (NDC 72789-009-30); b) 60 tablets (NDC 72789-009-60); c) 90 tablets (NDC 72789-009-90); d) 180 tablets (NDC 72789-009-93); e) 100 tablets (NDC 49483-0623-01) bottles, Rx only PD-Rx Pharmaceuticals Incorporated, Oklahoma City, OK 73127
Reason for recall
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Distribution pattern
United States.
Code information
Lots: a) A20B02, I19D03, J19A98, K19E32, L19C86 Exp. 12/31/2020; b) I19D55, I19F50, K19A18, K19D87, L19B34, L19D23, L19E74 Exp. 12/31/2020; c) I19E91, I19F33, J19B88, J19E70, K19D26, L19A65 Exp. 12/31/2020; d) I19C21 Exp. 08/21/2020, I19C57, J19C21, J19C67, K19B53, L19C77, L19E44 Exp. 12/31/2020; e) XP9004 Exp. 12/31/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1333-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026